Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital.
Title | Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Tsentemeidou, A., Sotiriou E., Vakirlis E., Sideris N., Lallas A., & Ioannides D. |
Journal | Arch Dermatol Res |
Date Published | 2020 Oct 22 |
ISSN | 1432-069X |
Abstract | Hidradenitis suppurativa (HS) is a difficult-to-treat chronic relapsing skin disease, which greatly impacts the quality of life. To bring forward real-life challenges in the decision-making process regarding HS treatment. A retrospective observational study was performed with treatment-related data derived from the HS archive of tertiary hospital-based First Department of Dermatology and Venereology of Aristotle University, Greece. Data were available for 121 patients, 63 men (52.7%) and 58 women (47.93%) with a mean age of 38 years. Doxycycline 100 mg twice daily for 1-2 weeks and then once daily for up to a total of 12 weeks was the most popular treatment choice (80 patients, 66.12%), administered for mild-to-moderate disease. Biologics were the second most frequently prescribed treatment, reserved for moderate-to-severe disease (adalimumab: 26 patients, 14.88%, infliximab: 2 patients, 1.65%). All in all, a wide variety of treatment regimens were implemented, with various combinations of topical and systemic agents. Real-life practice reflects the relative paucity of high-quality evidence regarding HS treatment and the absence of a unanimously preferable therapeutic option, leaving both dermatologists and patients defenceless against disease progress and sequelae. |
DOI | 10.1007/s00403-020-02150-6 |
Alternate Journal | Arch Dermatol Res |
PubMed ID | 33094412 |